The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...
The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from ...
Panelists discuss how to optimize treatment selection and sequencing for a 65-year-old patient with standard-risk, transplant ...
Panelists discuss how the IMROZ trial demonstrated improved outcomes with quadruplet therapy combining daratumumab, lenalidomide, melphalan, and prednisone in patients with transplant-ineligible newly ...
The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and ...
CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.
David M. Waterhouse, MD, MPH, and Molly Mendenhall, MBOE, LSSBB, BSN, RN, discuss how the implementation of Lean Six Sigma methodology at Oncology Hematology Care in Cincinnati, Ohio, has transformed ...
Andrew Kuykendall, MD, discusses the rationale behind choosing to evaluate fedratinib in a phase 2 study for patients with atypical chronic myeloid leukemia, chronic neutrophilic leukemia, ...
During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants ...
Ashraf Z. Badros, MB, ChB, discusses the results of the phase 3 AURIGA trial which evaluated daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.
The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...
Panelists discuss the findings from the DESTINY-Breast12 study, focusing on the efficacy and safety of trastuzumab deruxtecan in patients with HER2-low breast cancer and its potential to expand ...